PreTect SEE
PreTect SEE is ideal as a quality control test for NILM cytology. It is an assay for the qualitative detection of the presence of Human Papillomavirus, HPV, E6/E7 oncogene mRNA from carcinogenic HPV types 16, 18 and 45.
PreTect SEE shows high clinical specificity, supported by a low positive rate in the general population.
This CE-IVD kit identify women that have carcinogenic expression of high-risk HPV types that may induce cervical cancer. Co-testing with PreTect SEE and Cytology will therefore improve the existing screening program sensitivity without an excessive follow-up workload.
With its high capacity and low cost the test is also ideal as stand-alone test in low-income countries.
Clinical benefits
Qualitative detection of E6/E7 mRNA expression from HPV 16, 18, 45
Intrinsic sample control ensuring sample adequacy
High clinical specificity minimising unnecessary interventions
High PPV for CIN2+
Enhanches identification of cervical adenocarcinoma
Low positivity rate in general population
CE-IVD kit
Test information
| Individual HPV genotyping | E6/E7 mRNA HPV 16, 18 and 45 |
| Intrinsic Sample Control (ISC): | Targeting mRNA from housekeeping gene |
| Sample type: | Cervical samples |
| Preservatives: | PreTect TM (PreTect AS) |
| PreservCyt/ThinPrep (Hologic) | |
| SurePath (BD Diagnostics) | |
| Input-material: | Isolated Nucleic Acid (DNA/RNA)* |
| Technology: | Real time NASBA |
| Isothermal amplification (41°C) | |
| Four specific molecular beacons | |
| Format: | 96-well PCR plate |
| Pre-filled with reagents | |
| n=94 | |
| Assay time: | ~ 150 minutes |
| Instrumentation: | Fluorescence reader / |
| RT-PCR (CFX-96/QuantStudio5) |
www.pretect.no